Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.47 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 2/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8198560 | 0.84 | CYP3A4 (0.60) | MAPTCYP2A6CYP3A4CYP2E1CYP2C9 | |
| SCHEMBL7905176 | 0.82 | CYP3A4 (0.58) | MAPTCYP2A6CYP3A4CYP2E1CYP2C9 | |
| SCHEMBL23108298 | 0.80 | CYP3A4 (0.50) | MAPTCYP2A6CYP3A4CYP2E1CYP2C9 | |
| SCHEMBL12180534 | 0.79 | RAB9A (0.59) | CYP2A6CYP3A4CYP2E1CYP2C9CYP2B6 | |
| SCHEMBL3291047 | 0.78 | MAPT (0.44) | MAPTCYP2A6ALDH1A1KDM4ENPC1 | |
| SCHEMBL18725058 | 0.77 | CYP3A4 (0.53) | CYP2A6CYP3A4CYP2E1CYP2C9CYP2B6 | |
| SCHEMBL2092693 | 0.76 | KDM4E (0.56) | CYP2A6CYP3A4CYP2E1CYP2C9CYP2B6 | |
| SCHEMBL13680611 | 0.76 | CYP3A4 (0.51) | MAPTCYP2A6CYP3A4CYP2E1CYP2C9 | |
| SCHEMBL23367838 | 0.76 | RAB9A (0.56) | MAPTCYP2A6CYP3A4CYP2E1CYP2C9 | |
| SCHEMBL14438067 | 0.76 | CYP3A4 (0.61) | MAPTCYP2A6CYP3A4CYP2E1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113613652-B | Benzimidazole compounds and their use in the treatment of alzheimer's disease or huntington's disease | 台湾卫生研究院 | 2022-08-23 | — | — | CN | disclosed |
| CN-113613652-A | Benzimidazole compounds and their use for treating alzheimer's disease or huntington's disease | 台湾卫生研究院 | 2021-11-05 | — | — | CN | disclosed |
| EP-3843724-A1 | BENZIMIDAZOLE COMPOUNDS AND USE THEREOF FOR TREATING ALZHEIMER'S DISEASE OR HUNTINGTON'S DISEASE | National Health Research Institutes (TW) | 2021-07-07 | — | — | EP | disclosed |
| US-10584120-B1 | Benzimidazole compounds and use thereof for treating Alzheimer's Disease or Huntington's Disease | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2020-03-10 | — | — | US | disclosed |
| US-20200071312-A1 | BENZIMIDAZOLE COMPOUNDS AND USE THEREOF FOR TREATING ALZHEIMER'S DISEASE OR HUNTINGTON'S DISEASE | NATIONAL HEALTH RES INST (TW) | 2020-03-05 | — | — | US | disclosed |
| WO-2020047360-A1 | BENZIMIDAZOLE COMPOUNDS AND USE THEREOF FOR TREATING ALZHEIMER'S DISEASE OR HUNTINGTON'S DISEASE | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2020-03-05 | — | — | WO | disclosed |
| WO-2020047360-A1 | BENZIMIDAZOLE COMPOUNDS AND USE THEREOF FOR TREATING ALZHEIMER'S DISEASE OR HUNTINGTON'S DISEASE | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2020-03-05 | — | — | WO | disclosed |
| US-20200071312-A1 | BENZIMIDAZOLE COMPOUNDS AND USE THEREOF FOR TREATING ALZHEIMER'S DISEASE OR HUNTINGTON'S DISEASE | NATIONAL HEALTH RES INST (TW) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071312-A1 | BENZIMIDAZOLE COMPOUNDS AND USE THEREOF FOR TREATING ALZHEIMER'S DISEASE OR HUNTINGTON'S DISEASE | GLUL, GLS2, GLS | MAPT 108/4885CYP2A6 2164/4885CYP3A4 1926/4885 |
| US-10584120-B1 | Benzimidazole compounds and use thereof for treating Alzheimer's Disease or Huntington's Disease | GLUL, GLS2, GLS | MAPT 108/4885CYP2A6 2164/4885CYP3A4 1926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.